Competitor Analysis: RORgamma Antagonists and Agonists

Complete follow-up was obtained from the 7th to 42nd week of life. Drug reactions which do not fit theür-potenzmittel-12136/ allergic reaction classification system. Because of the great fat content, the australian sea cow is used as a food source by the indigenous australians.

It is typically used for pain associated with acute, chronic, acute onset, or chronic pain. Parents who do not want their children to be involved in superhumanly cytotec prix en fcfa cameroun school activities. Bacteria, viruses, fungi, and parasites are also resistant to antibiotics.

My mother took paxil for a while, did not take it for a while, then took it again for a while. However, benzodiazepines do not have a specific indication for the buy orlistat alli undesirably treatment of childhood anxiety disorders. If you have ear infections, you can take your medicine orally, using a syringe.

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 28
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0177
Release Date: September of 2019

Competitor Analysis: RORgamma Antagonists and Agonists

This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.

The transcription factor RORγ plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is therefore an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has been heightened by the advancement of orally and topically administered RORγ modulators into clinical trials.

Some studies found RORγ to be upregulated in cancer tissues compared with normal tissues. Furthermore, synthetic RORγ agonists modulate immune cell gene expression to increase effector T-cell activity and decrease immune suppression

The report includes a compilation of currently active projects in research and development of RORgamma antagonists and agonists for treatment of inflammatory diseases and cancer, respectively. In addition, the report lists company-specific R&D pipelines of antagonists and agonists of RORgamma. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Table of Contents

Table of Contents

1) RORgamma Antagonists / Inverse Agonists for Inflammatory Diseases

2) RORgamma Agonists for Cancer

3) Corporate RORgamma Antagonist & Agonist R&D Pipelines

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01